MersV1, PubMed, Checkpoint, bibRecord, 000C36

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.

Identifieur interne : 000C36 ( PubMed/Checkpoint ); précédent : 000C35; suivant : 000C37

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.

Auteurs : Christopher M. Coleman [États-Unis] ; Thiagarajan Venkataraman [États-Unis] ; Ye V. Liu [États-Unis] ; Gregory M. Glenn [États-Unis] ; Gale E. Smith [États-Unis] ; David C. Flyer [États-Unis] ; Matthew B. Frieman [États-Unis]

Source :

Vaccine [ 1873-2518 ] ; 2017.

RBID : pubmed:28237499

Descripteurs français

English descriptors

KwdEn :
- Adjuvants, Immunologic (administration & dosage), Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Coronavirus Infections (prevention & control), Disease Models, Animal, Mice, Inbred BALB C, Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (immunology), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology), Vaccines, Virus-Like Particle (administration & dosage), Vaccines, Virus-Like Particle (genetics), Vaccines, Virus-Like Particle (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Vaccines, Synthetic, Vaccines, Virus-Like Particle, Viral Vaccines.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- genetics : Middle East Respiratory Syndrome Coronavirus, Spike Glycoprotein, Coronavirus, Vaccines, Synthetic, Vaccines, Virus-Like Particle, Viral Vaccines.
- immunology : Middle East Respiratory Syndrome Coronavirus, Spike Glycoprotein, Coronavirus, Vaccines, Synthetic, Vaccines, Virus-Like Particle, Viral Vaccines.
- prevention & control : Coronavirus Infections.
- Animals, Disease Models, Animal, Mice, Inbred BALB C.

Abstract

The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces neutralizing antibodies in vivo, all of which, make the S protein an ideal target for anti-MERS-CoV vaccines. In this study, we demonstrate protection induced by vaccination with a recombinant MERS-CoV S nanoparticle vaccine and Matrix-M1 adjuvant combination in mice. The MERS-CoV S nanoparticle vaccine produced high titer anti-S neutralizing antibody and protected mice from MERS-CoV infection in vivo.

DOI: 10.1016/j.vaccine.2017.02.012
PubMed: 28237499

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000D66
to stream PubMed, to step Curation: 000D66

Links to Exploration step

pubmed:28237499

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.</title>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Venkataraman, Thiagarajan" sort="Venkataraman, Thiagarajan" uniqKey="Venkataraman T" first="Thiagarajan" last="Venkataraman">Thiagarajan Venkataraman</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V" last="Liu">Ye V. Liu</name>
<affiliation wicri:level="2"><nlm:affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M" last="Glenn">Gregory M. Glenn</name>
<affiliation wicri:level="2"><nlm:affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E" last="Smith">Gale E. Smith</name>
<affiliation wicri:level="2"><nlm:affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C" last="Flyer">David C. Flyer</name>
<affiliation wicri:level="2"><nlm:affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States. Electronic address: mfrieman@som.umaryland.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28237499</idno>
<idno type="pmid">28237499</idno>
<idno type="doi">10.1016/j.vaccine.2017.02.012</idno>
<idno type="wicri:Area/PubMed/Corpus">000D66</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D66</idno>
<idno type="wicri:Area/PubMed/Curation">000D66</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D66</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000C36</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C36</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.</title>
<author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Venkataraman, Thiagarajan" sort="Venkataraman, Thiagarajan" uniqKey="Venkataraman T" first="Thiagarajan" last="Venkataraman">Thiagarajan Venkataraman</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
<author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V" last="Liu">Ye V. Liu</name>
<affiliation wicri:level="2"><nlm:affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M" last="Glenn">Gregory M. Glenn</name>
<affiliation wicri:level="2"><nlm:affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E" last="Smith">Gale E. Smith</name>
<affiliation wicri:level="2"><nlm:affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C" last="Flyer">David C. Flyer</name>
<affiliation wicri:level="2"><nlm:affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States. Electronic address: mfrieman@som.umaryland.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201</wicri:regionArea>
<placeName><region type="state">Maryland</region>
<settlement type="city">College Park (Maryland)</settlement>
</placeName>
<orgName type="university">Université du Maryland</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Animals</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Disease Models, Animal</term>
<term>Mice, Inbred BALB C</term>
<term>Middle East Respiratory Syndrome Coronavirus (genetics)</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (genetics)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (genetics)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Vaccines, Virus-Like Particle (administration & dosage)</term>
<term>Vaccines, Virus-Like Particle (genetics)</term>
<term>Vaccines, Virus-Like Particle (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (genetics)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Anticorps neutralisants (sang)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (génétique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Glycoprotéine de spicule des coronavirus (génétique)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Infections à coronavirus ()</term>
<term>Modèles animaux de maladie humaine</term>
<term>Souris de lignée BALB C</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (génétique)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Vaccins à pseudo-particules virales (administration et posologie)</term>
<term>Vaccins à pseudo-particules virales (génétique)</term>
<term>Vaccins à pseudo-particules virales (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Vaccines, Synthetic</term>
<term>Vaccines, Virus-Like Particle</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
<term>Vaccins à pseudo-particules virales</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Synthetic</term>
<term>Vaccines, Virus-Like Particle</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
<term>Vaccins à pseudo-particules virales</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
<term>Vaccins à pseudo-particules virales</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Synthetic</term>
<term>Vaccines, Virus-Like Particle</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Infections à coronavirus</term>
<term>Modèles animaux de maladie humaine</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces neutralizing antibodies in vivo, all of which, make the S protein an ideal target for anti-MERS-CoV vaccines. In this study, we demonstrate protection induced by vaccination with a recombinant MERS-CoV S nanoparticle vaccine and Matrix-M1 adjuvant combination in mice. The MERS-CoV S nanoparticle vaccine produced high titer anti-S neutralizing antibody and protected mice from MERS-CoV infection in vivo.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28237499</PMID>
<DateCompleted><Year>2017</Year>
<Month>12</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>35</Volume>
<Issue>12</Issue>
<PubDate><Year>2017</Year>
<Month>03</Month>
<Day>14</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.</ArticleTitle>
<Pagination><MedlinePgn>1586-1589</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(17)30193-7</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2017.02.012</ELocationID>
<Abstract><AbstractText>The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces neutralizing antibodies in vivo, all of which, make the S protein an ideal target for anti-MERS-CoV vaccines. In this study, we demonstrate protection induced by vaccination with a recombinant MERS-CoV S nanoparticle vaccine and Matrix-M1 adjuvant combination in mice. The MERS-CoV S nanoparticle vaccine produced high titer anti-S neutralizing antibody and protected mice from MERS-CoV infection in vivo.</AbstractText>
<CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coleman</LastName>
<ForeName>Christopher M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Venkataraman</LastName>
<ForeName>Thiagarajan</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Ye V</ForeName>
<Initials>YV</Initials>
<AffiliationInfo><Affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Glenn</LastName>
<ForeName>Gregory M</ForeName>
<Initials>GM</Initials>
<AffiliationInfo><Affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smith</LastName>
<ForeName>Gale E</ForeName>
<Initials>GE</Initials>
<AffiliationInfo><Affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Flyer</LastName>
<ForeName>David C</ForeName>
<Initials>DC</Initials>
<AffiliationInfo><Affiliation>Novavax, Inc., 22 Firstfield Rd, Gaithersburg, MD 20852, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Frieman</LastName>
<ForeName>Matthew B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo><Affiliation>University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, United States. Electronic address: mfrieman@som.umaryland.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI095569</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>02</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Coronavirus</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">Mouse model</Keyword>
<Keyword MajorTopicYN="Y">Nanoparticle vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>12</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>01</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>02</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>2</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>12</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>2</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28237499</ArticleId>
<ArticleId IdType="pii">S0264-410X(17)30193-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2017.02.012</ArticleId>
<ArticleId IdType="pmc">PMC5423355</ArticleId>
<ArticleId IdType="mid">NIHMS855075</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2015 Apr;89(8):4696-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25653445</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Transl Med. 2016 Feb 17;8(326):326ra21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26888429</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2011 Apr;10(4):401-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21506635</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2017 Jan 3;91(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27807241</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Protoc Microbiol. 2015 May 01;37:15E.2.1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26344219</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Mol Immunol. 2016 Mar;13(2):180-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25640653</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2014 Feb;95(Pt 2):408-412</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24197535</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1894-903</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26164863</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2014 May;88(9):5195-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24574399</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Res. 2015 Nov;25(11):1237-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26391698</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26216974</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2016 Sep;133:165-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27468951</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Jul;22(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27191188</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2012;7(11):e50852</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23226404</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 May 30;32(26):3169-3174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Aug;22(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27439020</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
<settlement><li>College Park (Maryland)</li>
</settlement>
<orgName><li>Université du Maryland</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name>
</region>
<name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C" last="Flyer">David C. Flyer</name>
<name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name>
<name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M" last="Glenn">Gregory M. Glenn</name>
<name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V" last="Liu">Ye V. Liu</name>
<name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E" last="Smith">Gale E. Smith</name>
<name sortKey="Venkataraman, Thiagarajan" sort="Venkataraman, Thiagarajan" uniqKey="Venkataraman T" first="Thiagarajan" last="Venkataraman">Thiagarajan Venkataraman</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C36 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000C36 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:28237499
   |texte=   MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:28237499" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki